SCHEMBL4854930

SCHEMBL4854930

CCc1ccc(C(O)c2ncccc2O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 2/20 0.39
LMNA P02545 2/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
MAPK1 P28482 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
EGLN1 Q9GZT9 1/20 0.34
TRPA1 O75762 1/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
PDE2A O00408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854942 0.76 L3MBTL1 (0.41) LMNAL3MBTL1MAPK1TSHRATM
SCHEMBL19303026 0.73 TSHR (0.48) P4HBLMNAL3MBTL1MAPK1ALDH1A1
SCHEMBL4861034 0.71 PRKDC (0.31) P4HBLMNA
SCHEMBL4853382 0.70 ALDH1A1 (0.53) L3MBTL1ALDH1A1TSHRCYP1A2CYP3A4
SCHEMBL30853079 0.70 ALDH1A1 (0.42) L3MBTL1ALDH1A1TSHRHPGDCYP2C19
SCHEMBL6899388 0.70 TP53 (0.54) LMNAL3MBTL1MAPK1ALDH1A1TSHR
SCHEMBL364693 0.69 GABRA1 (0.50) LMNAL3MBTL1ALDH1A1TSHRTDP1
SCHEMBL31155959 0.69 GABRA1 (0.50) LMNAL3MBTL1ALDH1A1TSHRTDP1
SCHEMBL9627663 0.69 ALDH1A1 (0.45) LMNAL3MBTL1ALDH1A1TSHRTDP1
SCHEMBL4853429 0.69 IDO1 (0.38) P4HBLMNAL3MBTL1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 P4HB 2703/4885LMNA 4561/4885L3MBTL1 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.